Advertisement

Topics

LIVIA Group Acquires Patheon Facility in Capua, Italy

20:00 EDT 20 Jul 2015 | Marketwired

DURHAM, NC--(Marketwired - July 21, 2015) - LIVIA Group, a German-based industrial holding, has entered into an agreement to acquire the Capua manufacturing facility and associated employees from Patheon, a leading global provider of outsourced contract development and manufacturing (CDMO) services for the pharma and biopharma industries. Capua, one of the world's largest independent microbial fermentation-based manufacturing facilities with 1,400m3
fermentor capacity, represents an exceptional investment opportunity for LIVIA in the highly attractive market of enzymes and small molecules.

"LIVIA Group is enthusiastic about working with Capua to build on their existing strong market position, through a focus on product development, a revitalized sales function and improved production efficiency," said Prof Dr Dr Peter Löw, Chief Executive and founder of LIVIA Group. "We are very pleased to be invested in the business and look forward to supporting its future growth."

Capua delivers enzymes, therapeutic proteins and high-value small molecules for applications in food, feed, pharma, agrochemical and fine chemical industry. The facility is both FDA and EMEA (Pharma cGMPs) approved as well as ISO 14001 certified and serves customers in more than 60 countries. In addition to its regular production, Capua offers pilot plant capabilities for customized product development, process scale-up and validation.

"We are very pleased to find a buyer for the Capua facility that is focused on servicing existing customers and adding new ones," said Lukas Utiger, president drug substance services at Patheon. "Selling the Capua site is part of Patheon's efforts to focus its core business strategy as a leading global provider of outsourced, end-to-end pharmaceutical development and manufacturing services. We elected to sell the operations to LIVIA Group, who is very focused on growing the operations and continuing to provide a positive work environment for employees."

About LIVIA Group

With funds under management amounting to more than EUR 500m, LIVIA Group is an independent industrial holding company and the investment firm of Prof Dr Dr Peter Löw, concentrating on a diverse spectrum of assets ranging from corporate, real estate, agricultural, emerging markets and opportunistic investments.

LIVIA Corporate Investments
is specializing in acquiring European corporate spin-offs / carve-outs and midsized companies with i) development potential through operational engagement, ii) below industry average profitability, iii) restructuring or transformation needs, or iv) synergies with existing platform-investments and a revenue size between EUR 20m to EUR 1.5bn. With over 220 successfully executed transactions, LIVIA's management has become a trusted partner among international corporates.

About Patheon

Patheon is a leading global provider of outsourced pharmaceutical development and manufacturing services. With approximately 8,700 employees worldwide, Patheon provides a comprehensive, integrated and highly customizable set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle.

:Stephan Herre+49 89 5527580:Tyler Gronbach+1 919 226 3165 NEXT ARTICLE

More From BioPortfolio on "LIVIA Group Acquires Patheon Facility in Capua, Italy"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...